Cambridge Cog Regulatory News (COG)

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED IN IT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO MIGHT CONSTITUTE A VIOLATION OF LOCAL APPLICABLE SECURITIES LAWS OR REGULATIONS.

25 April 2016

Cambridge Cognition Holdings Plc

("Cambridge Cognition" or the "Company")

Placing to raise £1.25 million

Cambridge Cognition Holdings plc, (AIM: COG), which specialises in development and marketing of computerised neuropsychological tests including those enabling the early detection of dementia, is pleased to announce an oversubscribed placing of 3,386,111 new ordinary shares of 1 pence each in the Company ("Ordinary Shares") ("Placing Shares") at a price of 37 pence per Placing Share (the "Issue Price") to raise gross proceeds of £1.25 million (the "Placing"). This includes 113,515 Placing Shares for which certain Directors of the Company intend to subscribe as detailed below.

About the Placing

The Company intends to use the proceeds of the placing to invest in:

· expanding sales infrastructure to accelerate sales growth in cash generative businesses;

· commercialising healthcare products:

· through Pharma Clinical Trials channel to generate near term income and validate technology;

· through corporate partners to access growing private and occupational health markets;

· healthcare technology innovations to address significant predictive and digital health opportunities; and

· advancing FDA and CE approvals.

Michael Lewis, Chairman; Steven Powell, Chief Executive Officer; and Nick Walters, Chief Financial Officer, intend to subscribe later today for 5,406, 40,541 and 67,568 Ordinary Shares respectively (also at a price of 37 pence per Ordinary Share).

Related Party Transaction

The participation of Euroblue Investments Limited as a substantial shareholder in the Company, in the Placing constitutes a related party transaction under the AIM Rules (the "Related Party Transaction"). The Directors consider, having consulted with finnCap, the Company's nominated adviser, that the terms of the Related Party Transaction are fair and reasonable insofar as shareholders of the Company are concerned.

Details of the Placing and Total Voting Rights

Pursuant to the Placing, the Company will issue 3,386,111 Placing Shares at the Issue Price. Application has been made to the London Stock Exchange for the Placing Shares to be admitted to trading on AIM and Admission is expected to occur on 28 April 2016. The Placing Shares will rank pari passu in all respects with the existing Ordinary Shares.

The Placing is conditional, inter alia, upon the placing agreement not having been terminated, and admission of the Placing shares having occurred by no later than 28 April 2016 (or such time and date as finnCap and Hybridan or the Company may agree, being not later than 6 May 2016). The Placing is not being underwritten.

Following Admission, the Company's enlarged issued share capital will comprise 20,429,235 Ordinary Shares. The Company holds no Ordinary Shares in treasury, therefore the total number of voting rights in the Company will be 20,429,235. This figure may be used by shareholders in the Company as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change in their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

Steven Powell, Chief Executive Officer, commented:

"We are pleased with the support of existing and new shareholders as we focus on driving growth and revenues and commercialising our healthcare products."

Enquiries: